title: Theranostic vesicles based on bovine serum albumin and poly(ethylene glycol)-block-poly(L-lactic-co-glycolic acid) for magnetic resonance imaging and anticancer drug delivery.
abstract: Presented in this article is the preparation of a new theranostic vesicle which exhibits excellent in vitro and in vivo T1 magnetic resonance (MR) imaging contrast effect and good anticancer drug delivery ability. The theranostic vesicle has been easily prepared based on an amphiphilic biocompatible and biodegradable dibock copolymer, poly(ethylene glycol)-block-poly(l-lactic-co-glycolic acid) (PEG-b-PLGA) and bovine serum albumin-gadolinium (BSA-Gd) complexes. Dynamic light scattering (DLS), transmission electron microscopy (TEM), UV-vis spectroscopy, and inductively coupled plasma atomic emission spectroscopy (ICP-AES) measurements confirmed the formation and physiological stability of BSA-Gd@PEG-b-PLGA vesicles. Furthermore, the in vitro and in vivo MR imaging experiments revealed their excellent T1-weighted MR imaging function. Red blood cell hemolysis and cytotoxicity experiments confirmed their good blood compatibility and low cytotoxicity. Doxorubicin (DOX) loading and release experiments indicated a more retarded release rate of DOX in those theranostic vesicles than sole PEG-b-PLGA nanoparticles without BSA. Overall, this new biocompatible and biodegradable vesicle shows promising potential in theranostic applications.
authors.affiliation: School of Materials Science and Engineering, Tongji University , 4800 Caoan Road, Shanghai 201804, People's Republic of China.
authors.forename: Qiuming
authors.initials: Q
authors.lastname: Liu
authors.forename: Hongshi
authors.initials: H
authors.lastname: Zhu
authors.forename: Jingya
authors.initials: J
authors.lastname: Qin
authors.forename: Haiqing
authors.initials: H
authors.lastname: Dong
authors.forename: Jianzhong
authors.initials: J
authors.lastname: Du
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005682:Gadolinium / Q000008:administration & dosage / Q000737:chemistry; D006367:HeLa Cells; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000175:diagnosis*; D010316:Particle Size; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000737:chemistry; D011098:Polyglactin 910 / Q000008:administration & dosage* / Q000737:chemistry; D012710:Serum Albumin, Bovine / Q000008:administration & dosage*; D013329:Structure-Activity Relationship; D013499:Surface Properties
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; C102418:poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer; D012710:Serum Albumin, Bovine; D011098:Polyglactin 910; D011092:Polyethylene Glycols; D004317:Doxorubicin; D005682:Gadolinium